AZ has nearly 50% of workforce in emerging markets as it keeps ‘sharp eye’ on costs
This article was originally published in Scrip
AstraZeneca has implemented a significant reallocation of resources from established to emerging markets, adding 6,400 ‘permanent’ personnel last year in the latter as it gears to expand and build capabilities in some of the most promising markets including China and Russia.
You may also be interested in...
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
The head of global vaccine and plasma segments, bioprocessing, at German multinational Merck discusses key aspects around evolving vaccine manufacturing to improve the efficiency and speed of response during a pandemic. Pre-existing manufacturing platforms, the executive says, could compress process development work and fast-track scale-up.
Glenmark and Sun Pharma introduce nintedanib generics in India at a fraction of the innovator product’s price, vying for a share of the IPF market where pirfenidone currently holds sway.